Repair Claims. Evidence, Ranked.

Start at base camp

Repair is not one event. It is a chain: inflammation is controlled, damaged surfaces close, cells move, blood vessels form, and tissue reorganizes. BPC-157, TB-500, and KPV enter that chain at different points. They also sit at different evidence levels.

BPC-157 has animal and cell findings around blood-vessel signaling, stomach protection, and wound models. Its published human record is tiny ^[1][2]. TB-500 is a short fragment of thymosin beta-4. Most encouraging repair studies concern the full parent protein, not the fragment sold under the TB-500 name ^[6][8]. KPV is a three-amino-acid fragment studied for inflammation, gut transport, and surface healing in cells and animals ^[13][16]. It has no published human trial in this corpus.

That is the frame. Mechanism sits at the bottom. Animal outcomes come next. Human safety and efficacy sit higher. The summit has not been reached for any compound here. This site maps the climb. It does not turn a model into a treatment claim.

The ascent of repair evidence

A mechanism can be credible and still fail as a therapy. The distinction drives this desk. A cell study can show that a signal changes. An animal model can show that a wound closes faster or inflammation falls. A controlled human trial must then test whether the same outcome occurs in people, at acceptable risk, under defined conditions. Each step answers a different question.

BPC-157 starts with a plausible vascular route. In mixed laboratory models it increased VEGFR2 activity, a receptor involved in new blood-vessel formation, and activated downstream nitric-oxide signaling ^[4]. A rat ulcer study reported faster tissue rebuilding ^[5]. The human evidence does not match that breadth. One safety pilot involved only two healthy adults and did not test repair efficacy ^[1]. A recent review found just three human pilot studies and no rigorous large trials ^[2].

TB-500 requires an identity check before any ascent can be scored. The commercial name generally denotes a seven-amino-acid fragment. Much of the efficacy literature concerns full-length thymosin beta-4. Structural work shows how that parent protein binds free actin, a core part of cell movement ^[10]. Reviews connect it with migration, angiogenesis, inflammation control, and scar biology ^[8]. Those findings cannot simply be assigned to the fragment.

KPV leads this editorial frame because the path is unusually clean at the mechanistic level. Inflamed intestinal tissue increases a transporter called PepT1. KPV uses that transporter to enter epithelial cells and suppress inflammatory signaling in models ^[13]. Delivery systems have then been built around that route and tested in mouse colitis ^[11][12]. The logic is strong. The clinical step is absent.

What are research peptides?

Peptides are short chains made from amino acids, the same small units used to build proteins. Their size does not make them simple. A short sequence can interact with receptors, transporters, enzymes, or structural proteins. It can also be broken down quickly before reaching a target. That is why mechanism, delivery, stability, and study design all matter.

The label research peptide describes an experimental subject, not a proven treatment class. None of the three compounds on this desk has an approved therapeutic indication in the source corpus. BPC-157 is investigational. TB-500 is an unapproved fragment and is prohibited in competitive sport. KPV has no validated human dosing, pharmacokinetics, efficacy, or clinical safety. Material sold outside formal studies also raises questions about identity and purity.

The pages therefore separate four layers. Identity states what molecule was actually tested. Mechanism states what it interacts with. Model evidence states what happened in cells or animals. Human evidence states what has been measured in people. The layers are not interchangeable. A persuasive pathway does not establish a clinical benefit. A favorable animal result does not establish human safety. A tiny safety study does not establish repair efficacy.

Read the altitude, not the headline

Three recurring errors flatten this field. The first is species drift: a rat, mouse, rabbit, or cell result is retold as if it occurred in people. The second is identity drift: full-length thymosin beta-4 evidence is retold as TB-500 fragment evidence. The third is endpoint drift: a laboratory marker of regeneration is treated as restored strength, comfort, or function.

Acsend Peptides keeps those boundaries visible. Quantitative statements carry numbered citations. Anecdotal reports remain labeled and separate from clinical findings. Safety gaps stay in the main text. The comparison page ranks the three files by evidence maturity. The FAQ answers the common questions without protocol language. The references page exposes the complete signed source set.

The result is intentionally austere. Repair biology is complex. The editorial rule is not. State what was studied. Name the model. Mark the missing step. Stop there.